Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MANKIND PHARMA Gains 4%; BSE HEALTHCARE Index Down 0.5%
Wed, 30 Oct 10:10

MANKIND PHARMA Gains 4%; BSE HEALTHCARE Index Down 0.5%Image source: Nikada/www.istockphoto.com

MANKIND PHARMA share price has zoomed 4% and is presently trading at Rs 2,639.8.

Meanwhile, the BSE HEALTHCARE index is at 42,979.4 (down 0.5%).

Among the top gainers in the BSE HEALTHCARE index today are POLY MEDICURE (up 4.1%) and CAPLIN POINT (up 2.4%).

Cipla (down 4.1%) and Dr. Reddys (down 2.8%) are among the top losers today.

Over the last one year, MANKIND PHARMA has moved up from Rs 1,753.3 to Rs 2,639.8, registering a gain of Rs 886.5 (up 50.6%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,385.2 to 42,979.4, registering a gain of 56.9% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 186.8%), SUVEN PHARMACEUTICALS (up 125.7%) and Glenmark Pharma (up 124.1%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 80,069.6 (down 0.4%).

The top losers among the BSE Sensex today are Sun Pharma (down 1.8%) and ICICI Bank (down 1.6%). The most traded stocks in the BSE Sensex are Power Grid Corp. and Tata Motors.

In the meantime, NSE Nifty is at 24,394.8 (down 0.3%). Cipla and Dr. Reddys are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 64,112.7 to 80,069.6, registering a gain of 15,956.9 points (up 24.9%).

MANKIND PHARMA Financial Update...

MANKIND PHARMA net profit grew 10.2% YoY to Rs 5,392 million for the quarter ended June 2024, compared to a profit of Rs 4,895 million a year ago. Net sales rose 12.2% to Rs 28,934 million during the period as against Rs 25,786 million in April-June 2023.

For the year ended March 2024, MANKIND PHARMA reported 48.3% increase in net profit to Rs 19,418 million compared to net profit of Rs 13,097 million during FY23. Revenue of the company grew 18.1% to Rs 103,348 million during FY24.

The current Price to earnings ratio of MANKIND PHARMA, based on rolling 12 month earnings, stands at 53.5.


Equitymaster requests your view! Post a comment on "MANKIND PHARMA Gains 4%; BSE HEALTHCARE Index Down 0.5%". Click here!